Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Search
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Facing lung cancer
Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
Arti-Cell® FORTE
.
Moving to Germany
We started in Germany, but we have offices all over the world.
Respimat media
BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
Facts about the INPULSIS™ trials
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® Cancer Vaccine
KISIMA® Cancer Vaccine
CD137/FAP agonist
CD137/FAP agonist
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Our core product areas
Our core product areas
International Postdocs realize their potential in Biberach
Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Our core product areas
VSV-GP
VSV-GP
Connect with your heart
If you know someone who has #type2diabetes, they are twice as likely to develop heart failure than those without.
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care